ARTICLE | Clinical News

Ampligen rintatolimod: Additional Phase III data

December 6, 2010 8:00 AM UTC

Additional data from the 40-week, double-blind, U.S. Phase III AMP-516 trial in 234 patients showed that patients treated with placebo had significant prolongation of QT intervals compared to patients treated with twice-weekly Ampligen (p=0.049). Hemispherx said the prolonged QT interval in the placebo group was associated with the use of concomitant medications known to prolong the QT interval, but are used by CFS patients to mitigate symptoms of their disease. Patients receiving Ampligen were able to significantly reduce their dependency on these same medications. Data were published in the Journal of Applied Research. ...